These results confirmed that TET3 could inhibit the phosphorylation level of GSK3β (mainly through Ser9 site) by activating the AKT signaling pathway, eventually to stabilize and promote the β-catenin expression in ESCC cells. This evidence concerns the gene GSK3B and esophageal squamous cell carcinoma.